Evidence map›Paper›PMID 31209771›Full record

ReviewHeart failure reviews2019

Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies.

Zijun Ge, Amy Li, James McNamara, Cris Dos Remedios, Sean Lal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Prognostic implications of one-year left ventricular systolic function after heart transplantation.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Neurohumoral Activation in Heart Failure.International journal of molecular sciences · 2023
    Review
  20. Changes of calcium cycling in HFrEF and HFpEF.Mechanobiology in medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zijun GeSydney Medical School, University of Sydney, Camperdown, Australia.
Amy LiBosch Institute, School of Medical Sciences, University of Sydney, Camperdown, Australia.
James McNamaraBosch Institute, School of Medical Sciences, University of Sydney, Camperdown, Australia.
Cris Dos RemediosBosch Institute, School of Medical Sciences, University of Sydney, Camperdown, Australia.
Sean LalSydney Medical School, University of Sydney, Camperdown, Australia. sean.lal@sydney.edu.au.ORCID http://orcid.org/0000-0002-5841-560X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure represents the end result of different pathophysiologic processes, which culminate in functional impairment. Regardless of its aetiology, the presentation of heart failure usually involves symptoms of pump failure and congestion, which forms the basis for clinical diagnosis. Pathophysiologic descriptions of heart failure with reduced ejection fraction (HFrEF) are being established. Most commonly, HFrEF is centred on a reactive model where a significant initial insult leads to reduced cardiac output, further triggering a cascade of maladaptive processes. Predisposing factors include myocardial injury of any cause, chronically abnormal loading due to hypertension, valvular disease, or tachyarrhythmias. The pathophysiologic processes behind remodelling in heart failure are complex and reflect systemic neurohormonal activation, peripheral vascular effects and localised changes affecting the cardiac substrate. These abnormalities have been the subject of intense research. Much of the translational successes in HFrEF have come from targeting neurohormonal responses to reduced cardiac output, with blockade of the renin-angiotensin-aldosterone system (RAAS) and beta-adrenergic blockade being particularly fruitful. However, mortality and morbidity associated with heart failure remains high. Although systemic neurohormonal blockade slows disease progression, localised ventricular remodelling still adversely affects contractile function. Novel therapy targeted at improving cardiac contractile mechanics in HFrEF hold the promise of alleviating heart failure at its source, yet so far none has found success. Nevertheless, there are increasing calls for a proximal, 'cardiocentric' approach to therapy. In this review, we examine HFrEF therapy aimed at improving cardiac function with a focus on recent trials and emerging targets.

Indexed as

Adrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAnimalsCardiotonic AgentsGenetic TherapyHeart FailureHumansMiceMineralocorticoid Receptor AntagonistsMolecular Targeted TherapyRenin-Angiotensin SystemSarcoplasmic Reticulum Calcium-Transporting ATPasesStroke VolumeVentricular RemodelingAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsCardiotonic AgentsMineralocorticoid Receptor AntagonistsSarcoplasmic Reticulum Calcium-Transporting ATPasesBasic sciencesHeart failureHumanTranslational

Identifiers

PMID31209771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.